WallStSmart

HCA Holdings Inc (HCA)vsHoneywell International Inc (HON)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Holdings Inc generates 102% more annual revenue ($75.60B vs $37.44B). HON leads profitability with a 12.6% profit margin vs 9.0%. HCA appears more attractively valued with a PEG of 1.35. HCA earns a higher WallStSmart Score of 69/100 (B-).

HCA

Strong Buy

69

out of 100

Grade: B-

Growth: 7.3Profit: 8.0Value: 10.0Quality: 6.0
Piotroski: 5/9Altman Z: 1.71

HON

Buy

50

out of 100

Grade: C-

Growth: 2.7Profit: 7.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HCAUndervalued (+59.9%)

Margin of Safety

+59.9%

Fair Value

$1326.31

Current Price

$484.02

$842.29 discount

UndervaluedFair: $1326.31Overvalued
HONSignificantly Overvalued (-416.2%)

Margin of Safety

-416.2%

Fair Value

$47.19

Current Price

$225.79

$178.60 premium

UndervaluedFair: $47.19Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HCA5 strengths · Avg: 9.0/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-8.3310/10

Conservative balance sheet, low leverage

Market CapQuality
$108.62B9/10

Large-cap with strong market position

P/E RatioValuation
17.1x8/10

Attractively priced relative to earnings

EPS GrowthGrowth
44.5%8/10

Earnings expanding 44.5% YoY

HON3 strengths · Avg: 8.7/10
Market CapQuality
$143.53B9/10

Large-cap with strong market position

Return on EquityProfitability
26.1%9/10

Every $100 of equity generates 26 in profit

Free Cash FlowQuality
$1.12B8/10

Generating 1.1B in free cash flow

Areas to Watch

HCA1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

HON4 concerns · Avg: 3.5/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
32.5x4/10

Premium valuation, high expectations priced in

Price/BookValuation
10.3x4/10

Trading at 10.3x book value

Revenue GrowthGrowth
-3.3%2/10

Revenue declined 3.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.35 suggests the stock is reasonably priced for its growth.

Bull Case : HON

The strongest argument for HON centers on Market Cap, Return on Equity, Free Cash Flow.

Bear Case : HCA

The primary concerns for HCA are Altman Z-Score.

Bear Case : HON

The primary concerns for HON are PEG Ratio, P/E Ratio, Price/Book.

Key Dynamics to Monitor

HCA profiles as a value stock while HON is a declining play — different risk/reward profiles.

HCA carries more volatility with a beta of 1.34 — expect wider price swings.

HCA is growing revenue faster at 6.7% — sustainability is the question.

HON generates stronger free cash flow (1.1B), providing more financial flexibility.

Bottom Line

HCA scores higher overall (69/100 vs 50/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

HCA Holdings Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Honeywell International Inc

INDUSTRIALS · CONGLOMERATES · USA

Honeywell International Inc. is an American publicly traded, multinational conglomerate headquartered in Charlotte, North Carolina. It primarily operates in four areas of business: aerospace, building technologies, performance materials and technologies (PMT), and safety and productivity solutions (SPS).

Want to dig deeper into these stocks?